Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, Chung H Kok, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Dang Phuong, Verity A Saunders, Jodi Braley, Agnes S Yong, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes
LEUKEMIA | NATURE PUBLISHING GROUP | Published : 2018
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). The ALLG CML8 study enrolled 40 imatinib-treated patients with undetectable BCR-ABL1 mRNA (approximately MR4.5). Molecular relapse was defined as detectable BCR-ABL1 on two consecutive tests or any single value >0.1%. With a median follow-up of 8.6 years (range 5.7-11.2 years), 18 patients remain in continuous TFR (45.0%; 95% confidence interval 31.9-63.4%). The latest relapse detected was 27 months after stopping imatinib. No patient progressed to advanced phase. Twenty-..View full abstract
Awarded by Australian National Health & Medical Research Council
The authors acknowledge the important contribution of the TWISTER study patients and coordinators, and the ALLG as the study sponsor. This research was funded by the Australian National Health & Medical Research Council (Project grant #1051965), the Royal Adelaide Hospital Health Services Charitable Gifts Board, and Novartis Pharmaceuticals.